Astellas Pharma Inc. has returned 1.2% year-to-date, outperforming the broader Medical sector's average decline of 5.8%. The stock holds a Zacks Rank of 1, or Strong Buy, and its full-year earnings consensus estimate has risen 19.6% over the past quarter. Within the Medical - Drugs industry, which has lost 8.6% so far this year, Astellas is also performing better. Another industry peer, Aurinia Pharmaceuticals, has gained 3.2% year-to-date and carries a Zacks Rank of 2, or Buy, with its current-year EPS estimate up 0.6% in three months.
Astellas Pharma Inc.Astellas has a Strong Buy rating (Zacks Rank 1) and its full-year earnings consensus estimate rose 19.6% over the past quarter, indicating positive analyst sentiment.
Aurinia Pharmaceuticals Inc